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Thalidomide is an anti-inflammatory and an anti-angiogenesis drug that is being used around the world for a variety of malig-
nant and inflammatory diseases. Is it justified to continue prescribing and developing thalidomide given the discovery of many 
well-known side effects including catastrophic birth defects? To answer this question, this paper will discuss the pharmacology 
and history of thalidomide, as well as many of its proposed mechanisms of action. The medical indications for the current use of 
thalidomide as well as for several newer and more potent derivatives are mentioned for their therapeutic results, as well as their 
adverse side effects. 
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Introduction to Thalidomide
“Thalidomide remains, arguably, the greatest disaster in medical 
history” (Greener, 2011). Thalidomide was introduced in 1957 
by a German pharmaceutical company as a sedative and hypnot-
ic drug. It was also widely used in several countries to alleviate 
morning sickness in early pregnancy. It was sold in more than 
forty-six countries without any testing for teratogenicity, as was 
common practice for new drugs at that time. More than 10,000 
children around the world developed severe birth defects, espe-
cially shortening or absence of limbs. There was also an increase 
in miscarriages and infant mortality. Remarkably, the United States 
Food and Drug Administration did not approve sale of thalido-
mide despite five requests from manufacturers. As a result, only 
seventeen babies were affected in the United States, probably 
from thalidomide purchased in Canada (Huang, et. al. 2008).
By 1961 production and distribution of thalidomide were 
banned worldwide. Due to the risk of teratogenicity, almost no 
research into the use of thalidomide took place for the next 
decade. The first new indication for thalidomide was in treating 
a complication of leprosy known as erythema nodosum lepro-
sum (ENL) (Sharma, et. al. 2007). Beginning in 1967, anecdotal 
reports of the use of thalidomide in cancer treatment began to 
be published. Some of the diseases treated were astrocytoma, 
multiple-myeloma, chronic lymphocytic leukemia, and malignant 
melanoma. New research is being done to investigate the mecha-
nism of action of this class of immunomodulatory drugs in various 
malignancies and in non-malignant conditions such as Alzheimer’s 
Disease and persistent erythema multiforme (He, et. al. 2013).
Methods
Articles and studies researched in this paper were obtained 
through the EBSCO and ProQuest databases with access pro-
vided by the Touro College Library. Additional research articles 
were obtained through the National Center for Biotechnology 
Information (NCBI) website and the Jackson Laboratory web-
site. Images and diagrams that are used throughout the paper 
were obtained from the research articles cited.
Chemical Analysis
Thalidomide is a racemic glutamic acid analogue also known as 
[+] alpha-[N-phthalidimo]-glutarimide. It consists of two linked 
rings: a glutamic ring and a phthalic ring. Because it contains a 
chiral carbon the molecule is unstable and can switch back and 
forth between two enantiomers which are mirror images of 
each other. This reaction takes place rapidly in water or body 
fluids. While only one state, the S-enantiomer is thought to be 
teratogenic, the safer state, the R-enantiomer, is not stable and 
cannot be preserved in the body.  (Bartlett, et. al. 2004)
Thalidomide has traditionally been synthesized by a multi-
step process which uses expensive ingredients and produces a 
very low yield. A recent research study by chemists at Stockton 
University in New Jersey reports on a new rapid synthesis of 
thalidomide and its analogs using easily obtained reagents which 
rapidly interact with the assistance of a microwave. It produces 
relatively high yields. The reaction of the corresponding anhy-
drides using DMAP (4-N, N- dimethylaminopyridine) as a base 
catalyst takes place in ten minutes at 150 degrees Celsius. The 
chemists developing this new method of production describe 
their innovation as a, “novel green one-pot synthetic technique.” 
(Benjamin, et. al. 2017)
Pharmacology
Thalidomide has an active half-life of 8 to 12 hours. It is bro-
ken down by hydrolysis in tissue fluids and metabolized by the 
liver using the cytochrome p450 system. Although it is absorbed 
slowly, it has a high oral bioavailability. The plasma concentration 
peaks after at least two hours. Little drug is bound to protein in 
the plasma. The average elimination half-life of both enantiomers 
is five hours. (Vargesson, et. al. 2015)
According the British Columbia Cancer Drug Manual ac-
cessed online, high fat meals increase the time to peak con-
centration. Thalidomide is distributed mostly in the internal 
organs such as the gastro-intestinal tract, liver and kidneys. It 
is found to cross the blood brain barrier and is also found in 
the ejaculate.
In 2004, a new derivative of thalidomide was introduced for 
treatment of multiple myeloma. Lenalidomide, under the trade 
name Revlimid is considerably more potent than thalidomide. 
It has an added amino group at position 4 of the phthaloyl 
ring and removal of a carbonyl group from the phthaloyl ring. 
Pomalidomide (3-aminothalidomide) was the second thalido-
mide analog to be used in treating multiple myeloma. It is even 
more potent than the analogs before it. A third thalidomide 
analog, Apremilast is now showing effectiveness as an oral treat-
ment for psoriasis and psoriatic arthritis. (Bartlett, et. al. 2004)
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Mechanism of Action: Innate immunity: Effects 
on Epidermal Regeneration, Soluble Mediators, 
and Natural Killer Cells
Studies of epidermal regeneration have shown that thalidomide 
increases human keratinocytes migration and propagation. 
Testing was done with a motility assay and thymidine incorpo-
ration assays to better understand how thalidomide promotes 
this proliferation. In addition, the chemokine IL-8 that promotes 
migration of neutrophils and keratinocytes significantly increas-
es with thalidomide treatment. Because of this, researchers have 
theorized that the mechanism with which thalidomide aids in 
wound healing is by promoting keratinocyte production and 
movement. This may be useful in explaining its ability to treat 
ulcerative diseases, such as Behcet’s (a rare disorder causing in-
flammation in blood vessels with symptoms that include mouth 
and genital sores, inflamed eyes, and rashes) and aphthous sto-
matitis (shallow sores inside the mouth or at the base of the 
gums that make it hard to eat or talk) (Paravar & Lee, 2008). 
The exact mechanism of thalidomide’s anti-inflammatory 
action via soluble immune mediators is still being investigated. 
However, researchers have linked thalidomide’s anti-inflamma-
tory action to its ability to speed up the degradation of messen-
ger RNA in blood cells. These effects have been analyzed in both 
human monocytes and mouse macrophages (Paravar, Lee, 2008). 
By reducing the half-life of the messenger RNA coding for 
TNF-alpha, (Tumor Necrosis Factor) it in turn reduces the 
blood serum level of TNF-alpha. TNF-alpha is a cell signaling pro-
tein (cytokine) involved in systemic inflammation. By reducing 
TNF-alpha, thalidomide is an effective treatment for inflamma-
tory diseases such as erythema nodosum leprosum (ENL) and 
lupus erythematosus (LE). Many studies have been performed 
that confirm this reduction of TNF-alpha. For example, 48-68% 
of patients with ENL have a reduction of TNF-alpha in the 
serum from their pretreatment levels. Tuberculosis patients also 
show reduced levels in in-vitro and in-vivo studies and patients 
gained a significant amount of weight while on the medication. 
HIV-1 patients also had reduced TNF-alpha levels while under 
treatment with thalidomide. A further confirmation comes from 
studies using rodent models of pancreatitis in which thalido-
mide was seen to have similar effects (He, et. al. 2013).
Another proposed mechanism of action involves thalido-
mide’s effects on Natural Killer (NK) cells which are vital in 
destroying tumor cells, intracellular pathogens, and cells in-
fected by viruses. Using in-vitro studies, thalidomide has been 
observed to enhance NK-cell-mediated lysis of cancerous cells. 
This was demonstrated in a study that co-cultured NK cells 
with the same patient’s cancerous cells. Additionally, thalidomide 
increases the secretion of NK cell activators such as IL-12 and 
specifically induces NK cell antitumor responses. In an in vivo 
study, the number of NK cells in a multiple myeloma patient 
were increased with thalidomide therapy. The results of these 
studies indicate that thalidomide’s ability to enhance NK-cells 
is the mechanism by which it aids in the treatment of multiple 
myeloma (Paravar, Lee, 2008). 
Adaptive immunity: B Cell Antibody Suppression, 
T Cell Stimulation
Thalidomide suppresses B cell antibody formation in studies 
primarily using New Zealand Black (NZB) and Murphy Roths 
Large (MRL) mice. These strains were chosen because they have 
a genetic predisposition to autoimmune disorders (The Jackson 
Laboratory Website, updated 2018). Thalidomide inhibits the 
usually increased production of splenic IgM in NZB mice and 
splenic and lymph node IgG1 in MRL mice. In clinical studies, 
leprosy patients receiving thalidomide and dapsone treatment 
had lower serum IgM levels than patients receiving dapsone 
alone. The combination of these studies suggests that thalido-
mide’s action may be based on its downregulatory effects on 
antibody production (Paravar & Lee, 2008). 
Thalidomide was shown to be able to co-stimulate T cells 
once they were already partially activated by the T cell receptor. 
Co-stimulation is an important mechanism for immune defense. 
A second signal is sent to naïve T cells which facilitates their ini-
tiation and further generation of an antigen-specific effector re-
sponse. The co-stimulatory effect of thalidomide can be used as 
an immunological adjuvant, that is, it can enhance the response 
to tumor antigens in cancer patients (Bartlett, et. al. 2004).
Reduction of Tumorigenesis: Apoptosis and 
Restriction of Tumor Growth, and Antiangiogenic 
Activity
Tumors grow and expand due to their ability to evade apopto-
sis. In studies, thalidomide has induced apoptosis (G1 growth 
arrest) in human cancerous cells. It has also been shown to 
decrease the expression of the apoptosis-suppressing protein 
Bcl-2 in blood and bone marrow of patients with multiple my-
eloma. Another mechanism proposed is thalidomide’s ability to 
induce monocyte apoptosis by involving the cytochrome c-de-
pendent pathway. (Cytochrome c is known for its role in the 
mitochondria as a key contributor in ATP synthesis. In our case, 
we are more interested in thalidomide’s stimulation of cyto-
chrome c’s other effect which is triggered when a cell receives 
an apoptotic stimulus. The cytochrome c is then released into 
the cytosol and triggers programmed cell death through apop-
tosis) (Paravar & Lee, 2008). 
In 1971, Dr. Judah Folkman of Harvard Medical School formu-
lated his hypothesis that tumor growth depends on angiogen-
esis, the formation of new blood cells in the malignant tissue. 
Thalidomide, as mentioned above, inhibits limb bud formation 
in the embryo. This led to the idea that the teratogenic and 
antiangiogenic actions may be related.
Dr. Folkman made the groundbreaking discovery that tumor 
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growth and angiogenesis were related when he was working on 
testing the efficacy of hemoglobin solutions as a substitute for 
blood transfusions. As a part of this study he injected isolated 
organs with mouse melanoma cells. He found that the tumors 
could not grow and spread in the isolated perfused organs, but 
when they transplanted these same tumor cells into mice, they 
were quickly vascularized and grew larger. After conducting 
more research trials to prove his hypothesis, Dr. Folkman pub-
lished an article in the New England Journal of Medicine that 
stated that tumor growth depends on angiogenesis and that in-
hibiting angiogenesis can be used to treat certain cancers. From 
1980 to 2005 Dr. Folkman’s lab worked on testing twelve angio-
genic inhibitors including interferon alpha, fumagillin, endostatin 
and, notably, thalidomide (Ribatti, 2008).
Angiogenesis, the development of new blood vessels, is vital to 
the growth and spreading of cancerous tumors. The cancer de-
grades basement membranes and extracellular matrix and brings 
endothelial cells towards an angiogenic stimulus. It also involves 
pericytes and smooth muscles cells as well. Various growth fac-
tors are also needed to form new blood vessels from preexisting 
micro vessels. These growth factors include vascular endothelial 
growth factor (VEGF), basic fibroblast growth factor (bFGF), and 
platelet-derived growth factor (PDGF) (Fialho, et. al. 2013).
One proposed mechanism for thalidomide’s antiangiogenic 
effect is its ability to inhibit VEGF and bFGF production, which 
thereby inhibits vessel growth. Studies using human endothelial 
cells showed that thalidomide inhibits VEFG secretion and cell 
migration and lowers the total number of capillaries. In studies 
using chicken embryonic chorioallantoic membrane (CAM) tha-
lidomide inhibited VEGF and bFGF induced vessel growth. In one 
trial done by the Department of Cellular and Molecular Biology 
and Pathogenic Agents of the University of Sao Paulo, twelve 
CAMs from chicken eggs were incubated with thalidomide im-
plants and analyzed after two days to review the percentage of 
vessel deterioration. The results showed significant regression 
of vessels in CAM that had thalidomide or thalidomide-loaded 
implants as compared to the negative control (NC) group and 
an implant not containing any drug (Fialho, et. al. 2013).
Another study proposed that thalidomide inhibits endothelial 
cell proliferation by inhibiting the binding of the SP-1 transcrip-
tion factor, which has many binding sites on the VEGF promoter. 
This protein usually binds to the VEGF promoter to initiate and 
activate the transcription of the gene directly. When its binding 
is inhibited, it causes less VEGF to be produced and therefore 
limits the cells’ growth (Yabu, et. al. 2005).
A third mechanism of action being researched is thalidomide’s 
ability to suppress the VEGF gene by downregulating the VEGF 
receptors Flk-1 and neuropilin-1. By reducing the productiv-
ity of the VEGF receptors, thalidomide lessens the effects of 
the vascular endothelial growth factor in general. This causes 
less signals for angiogenesis to be sent, so the body forms less 
vasculature. With a smaller supply of blood, the growing limbs 
do not receive enough oxygen and nutrients, and they subse-
quently do not grow properly and result in under developed or 
malformed limbs (Yabu, et. al. 2005).
 A study done using zebrafish embryos and Human Umbilical 
Vein Cells (HUVEC) showed promising results in this area. The 
thalidomide treated embryo was shorter in length than the con-
trol. In addition, the lumens of the dorsal artery and posterior 
cardinal vein were clearly seen (with hematoxylin and eosin 
staining) in the control but were so reduced in the embryo 
treated with thalidomide that they were barely visible (Yabu, 
et. al. 2005).
Teratogenesis
Over the past fifty years, many separate models for thalidomide 
embryopathy have been proposed, however a full understand-
ing of its mechanism of action is still incomplete. The proposed 
theories are not necessarily mutually exclusive. And it is possible 
that multiple mechanisms of action are each involved to some 
extent. Additional theories include nerve toxicity, inhibition of 
cell adhesion molecules and effects on chondrogenesis. 
One breakthrough discovery revealed that Cereblon (CRBN), 
a protein encoded by the CRBN gene, may be the primary tar-
get for binding by thalidomide. The authors found that thalid-
omide binds directly to CRBN, a substrate receptor for the 
CUL4A-DDB1 E3 ubiquitin ligase, a protein that employs an E2 
ubiquitin-conjugating enzyme that carries ubiquitin, recognizes a 
protein substrate, and assists the transfer of ubiquitin from the 
E2 to the protein substrate. The ubiquitin is used to tag specific 
proteins to be broken down by proteasomes. This binding in-
hibits the activity of the assembled E3 ubiquitin ligase complex 
so that it does not tag the specific proteins, and an unknown 
substrate is allowed to accumulate. This in turn effects the ex-
pression of the fibroblast growth factor eight (FGF8) and causes 
growth defects. Thus, the action of the E3 ubiquitin ligase com-
plex is necessary for limb outgrowth (particularly in zebrafish) 
and by disrupting this complex, thalidomide induces teratogenic 
effects. Consequently, they demonstrated that the deformities 
caused by thalidomide were directly mediated through stopping 
its inhibition of CRBN. In zebrafish and chickens, when they 
used an overexpression of a CRBN mutant that does not bind 
thalidomide, they did not notice the defects usually caused by 
this drug, proving that it is the binding of the drug to CRBN that 
is responsible for the embryopathy effect (Ito. et. al. 2010).
Following this discovery, CRBN was also shown to be cru-
cial for the mechanism of action of thalidomide’s anti-myeloma 
properties, as well as other immune-modulatory drugs (IMiDs). 
One of the downstream targets of CRBN was shown to be in-
terferon regulatory factor 4 (IRF4). This protein which regulates 
the transcription of interferons is essential for myeloma cell 
survival and is downregulated by IMiD therapy (Zhu, et. al. 2013).
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A recent series of experiments supported in part by the 
National Cancer Institute further confirmed the hypothesis 
that antiangiogenesis and teratogenesis are related. The re-
searches tested a variety of angiogenesis inhibitors, including 
thalidomide and its analog CPS49, using zebrafish and chicken 
embryo models. They focused on assessing the developmental 
defects and teratogenic effects that the drugs caused. They 
concluded that different classes of angiogenesis inhibitors, 
regardless of the molecular target or specific mechanism of 
action, are teratogenic to chicken embryos. This study also 
proved that using chicken embryos and zebrafish embryos is 
a valid way to screen new drugs for teratogenic effects before 
they are used in clinical trials on women of childbearing age 
(Beedie, et. al. 2016).
New Research in Treatments Using Thalidomide 
and Its Derivatives: Multiple Myeloma (MM)
Multiple Myeloma is a type of blood cancer that affects plasma 
cells. In multiple myeloma, malignant plasma cells amass in the 
bone marrow crowding out the normal plasma cells that help 
fight infection. This disease can damage the bones, immune sys-
tem, kidneys, and cause anemia. A randomized trial compared 
the costs and benefits of using a melphalan (chemotherapy) and 
prednisone (steroid) treatment in conjunction with thalidomide 
(MPT) as opposed to melphalan and prednisone (MP) alone. The 
testing was done on 135 elderly patients over the age of 65 with 
MM who were ineligible for stem-cell transplants. The results 
showed a significant increase in the median progression-free 
survival (PFS) of patients using a combination of drugs that in-
cluded thalidomide. PFS is the length of time during and after 
the treatment of a disease that a patient lives with the disease 
but it does not get worse. Also, the overall survival (OS) rate 
was 52 months as opposed to only 32 months for patients using 
only melphalan and prednisone.  The following graph compares 
the progression-free survival rate of patients using MPT versus 
MP treatment. The MPT group has a significantly higher PFS rate. 
The Y axis is the fraction of living patients who began in the 
study. Both the MPT and MP groups start at 1.00, meaning that 
100% of participants are alive. The X axis is the months of the 
treatment. The MPT group has a higher PFS rate during the forty 
months of the trial. The P value is 0.02, meaning the results are 
statistically significant (Sacchi, et. al. 2011).
One downside of adding thalidomide to the treatment reg-
iment is the adverse side-effects that were more frequent in 
patients using thalidomide, which will be discussed in more de-
tail in the “Adverse Effects of Thalidomide” section of this paper. 
Researchers observed a significant increase in neutropenia, 
deep venous thrombosis, infection, and peripheral neuropathy. 
The incidence of toxicity correlates with the drug dosage. The 
study concluded that while including thalidomide in the therapy 
showed an increase in activity against MM, it came with a sub-
stantial cost, which will be discussed later.
Trials have also been conducted using the second-generation 
thalidomide derivate, lenalidomide.  In a randomized, controlled 
clinical trial, lenalidomide therapy (in combination with dexa-
methasone, a corticosteroid, or with melphalan and prednisone) 
significantly improved PFS in patients with newly diagnosed MM 
who were not eligible for stem-cell transplants as compared to 
MP treatment alone. These improvements in progression-free 
survival were also reflected in patients’ health-related quality of 
life (McCormack, 2015). 
In general, the analog was found to have improved efficacy and 
increased tolerability as compared to thalidomide. Although the 
treatment regiments had similar efficacy results, lenalidomide was 
observed to have fewer toxic side-effects than its parent drug. The 
continuous use of lenalidomide did not have a negative impact on 
the drug’s tolerability. It also did not increase the cases of neutro-
penia as compared with shorter-term use of the drug. With new 
analogs, melphalan and prednisone plus a thalidomide-type drug 
could be considered the new standard of care for the treatment 
of patients with MM over age 65 years and for younger patients 
who are transplant-ineligible (McCormack, 2015).
Recent studies are working on understanding lenalidomide’s 
mechanism of action. They propose that it affects signal trans-
duction, also known as cell signaling, which leads to the sup-
pression of COX-2 but not COX-1. This can partly explain its 
selective efficacy on cells. Meaning, it is able to be more selective 
in the cells it targets so it can have a greater potency with less 
side effects. Even though the exact molecular targets of lena-
lidomide are not well known, its activity across a spectrum of 
conditions highlights the possibility of multiple target sites of 
action (Kotla, et. al. 2009).
Malignant Melanoma
Malignant melanoma is the most aggressive and life-threatening 
skin cancer. It develops in the melanocytes and has a very high 
Figure 1. Depiction of the downstream targets of thalidomide that 
may lead to its teratogenic properties (Zhu, et. al. 2013).
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tendency to spread to other parts of the body. Symptoms can 
include a new, unusual growth or a change in an existing mole. 
Brain metastases will develop in almost half of the patients with 
advanced melanoma and in 15-20% of these patients, the central 
nervous system is the first site of relapse. The overall survival rate 
is very short, only two to four months (Vestermark, et. al. 2008).
In one study, the antitumor activity and toxicity of thalidomide 
was evaluated in patients with phase II brain metastases related 
to metastatic melanoma. Thalidomide was administered orally 
to patients, with the dose increasing over a one-month period 
from 100 mg per day to 400 mg per day. Twenty-five men and 
eleven women with a median age of forty-eight years were en-
rolled in the study. The average survival rate for the study group 
was unchanged from historical data. Median PFS was 1.7 months 
and OS was 3.1 months. Although thalidomide showed limited 
activity against the metastatic melanoma in the central nervous 
system, minor effects on peripheral tumor manifestation were 
noted. This led researchers to conclude that thalidomide may 
one day be part of the treatment plan for patients with that 
form of metastasis in the future. Researchers also concluded 
that more investigation should be done using thalidomide in 
combination with Temozolomide, a cytotoxic chemotherapy 
drug (Vestermark, et. al. 2008).
Persistent Erythema Multiforme
Erythema multiforme is a common, usually self-limited disease 
which predominantly affects patients in their 20s and 30s. Its 
symptoms include target shaped lesions (circular red patches 
with central clearing) on the skin and mucous membranes. 
There are three clinical subgroups of erythema multiforme: 
classical, recurrent, and persistent erythema multiforme. The 
most severe form is the persistent erythema multiforme 
which can leave a patient stricken with continuous lesions. No 
potential cause has been found yet, so this subgroup is defined 
as idiopathic. 
Thalidomide can be effectively used as a treatment for this 
skin condition. It was initially introduced as a treatment for 
persistent erythema multiforme as early as the 1980’s because 
of its immunomodulatory and anti-inflammatory effects. The 
following case report in the recent literature illustrates its 
effectiveness. A fifteen-year-old boy in the Republic of China 
experienced a sudden onset of target-like lesions on his trunk 
and limbs. Although the wounds healed within two weeks, new 
eruptions continued to appear. After unsuccessful treatment 
attempts with oral corticosteroids and topical agents as well 
as the antiviral drug valaciclovir, thalidomide was prescribed 
to the patient. After two weeks of administering 100 mg per 
day, the lesions gradually healed, and no new ones developed. 
After two months of slowly reducing the dosage, there was no 
recurrence of disorder. The researchers noted that because of 
the risk of neuropathy associated with taking daily doses of this 
medication, clinical vigilance and regular neurological exams are 
advised (Chia-Wei, et. al. 2008).
Cutaneous Lupus Erythematosus (CLE)
Cutaneous Lupus Erythematosus is an autoimmune disease, 
which affects multiple organ systems in the body. In this disease 
an individual’s own immune system attacks various cells causing a 
wide variety of symptoms. Typically, it causes extensive, disfiguring 
lesions. Although these lesions are not life threatening, they can 
be very itchy or painful. Many patients respond to standard treat-
ment methods such as sunscreen, topical corticosteroids, or oral 
antimalarial drugs. However, for cases in which these treatments 
did not prove useful, or if the CLE was severe, thalidomide can be 
an important therapeutic option (Sharma, et. al. 2007).
In a study done by the Department of Dermatology at the 
University Hospital of Leuven, Belgium, thirty patients received 
thalidomide treatment for refractory CLE over fifteen years 
(from February 1998 to August 2013.) Each of these patients 
had previously tried at least two different drug treatments 
with no success. All of them were required to follow vigorous 
contraceptive methods because of thalidomide’s known terato-
genic properties. Patients received an initial dose of 50 mg per 
day, which was increased to 100 mg if the CLE was extensive. 
Although six patients prematurely stopped treatment due to 
the negative side-effects, all patients who continued in the study 
experienced improvements within 1-9 weeks after beginning 
treatment. A high rate of relapse (73%) was observed in patients 
who stopped thalidomide treatment. In addition, five patients 
were not able to be weaned off the drug due to flare-ups of 
CLE when they attempted to taper off the doses. The research-
ers concluded that while thalidomide treatment for CLE does 
have strong efficacy, because of its considerable risk of polyneu-
ropathy, it should only be considered as a possible therapy for 
severe cases of CLE or for patients who have exhausted other 
treatment options without significant relief (Baret, et. al. 2015).
In another study done on twenty-five patients in India suffering 
from various inflammatory skin diseases, including discoid lupus 
erythematosus, thalidomide was found to be an effective treat-
ment. Of the seven patients with LE, four had excellent response, 
two had partial response and one discontinued treatment due 
to deep vein thrombosis (DVT). The authors recommended tha-
lidomide as an effective treatment but advised physicians to be 
watchful of thrombo-embolic events (Sharma, et. al. 2007).
Erythema Nodosum Leprosum (ENL)
When the author’s father, Stanley Newfield MD, was a young 
dermatology resident training at the United States Public Health 
Service Hospital in Staten Island, New York he was involved in 
diagnosing and treating many cases of leprosy, also known as 
Hansen’s disease. This research interest was perhaps especially 
appropriate since he is a kohen, the traditional caretaker for 
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people suffering from tzoras (leprosy) in the Torah. 
As a federal institution, his hospital was responsible for car-
ing for patients with transmissible infectious diseases. Leprosy 
patients were referred from a large area of the north-east-
ern United States for treatment. One of the complications of 
leprosy is the immune-system reaction known as Erythema 
Nodosum Leprosum. ENL is characterized by the presence of 
many inflammatory skin nodules and symptoms such as fever, 
arthritis, eye inflammation, neuritis, and swollen lymph nodes.  It 
was observed that many patients suffered from ENL, which was 
even more distressing to them than some of the other leprosy 
symptoms such as loss of sensation in the extremities and/or 
exaggerated skin folds on the face. 
Dr. Newfield explained that he was surprised, back in 1979, to 
find that the infamous drug, thalidomide, was the miraculously 
effective treatment for ENL. He was well-aware of the tera-
togenic effects of the drug which he learned about in detail in 
medical school. Now this same drug was resurrected for a new 
use, albeit with strong precautions to avoid administration to 
pregnant women. Due to his involvement in leprosy treatment, 
he was coauthor of a research report on the epidemiology of 
leprosy in New York City, which was published in the presti-
gious Journal of the American Medical Association.  
Many people have a fear of leprosy since it is transmissible 
through contact with an infected patient. However, this seems 
to require prolonged exposure, usually in a household setting. 
The research verified that very few leprosy patients acquire the 
disease in the continental United States, rather they brought 
the disease with them when they immigrated to this country. 
The average latent period from entering the United States until 
onset of symptoms was 4.8 years, with a range of 0 to 38 years 
(Levis, et. al. 1982).
Almost forty years have passed since thalidomide was first 
used for ENL treatment, and it remains the drug of choice for this 
condition, as evidenced by two current research reports originat-
ing from India, a country with a large number of leprosy patients. 
The first paper reports on eleven patients with ENL. Six of those 
patients had excellent response to thalidomide and five had to 
stop treatment prematurely due to side-effects (most commonly 
DVT but also rashes and tremors.) (Sharma, et. al. 2007) In the 
second study following one hundred patients diagnosed with 
ENL, the group of fifty patients treated with thalidomide had a 
faster and longer lasting clinical response than the control group 
of fifty patients treated with prednisolone, a strong steroid med-
ication. Patients on thalidomide also experienced fewer relapses 
of their cutaneous symptoms (Kaur, et. al. 2009).
Animal Models of Alzheimer’s Disease (AD)
Alzheimer’s Disease is a degenerative disease that destroys 
memory and other important mental functions. This is an in-
curable condition that afflicts an estimated 5.7 million people 
in the United States, mostly over the age of sixty-five. Research 
studies are currently being performed on a mouse model of AD. 
In one study, healthy mice were injected with streptozotocin 
(STZ), a chemical that causes AD-like cognitive deficits. In this 
study, one group of mice were pre-treated with thalidomide. 
Learning and memory behaviors were evaluated on the seven-
teenth, eighteenth and nineteenth days of the study using the 
Morris water maze test. In this test, a mouse is placed in the 
center of a circular pool and must find the hidden platform that 
allows it to escape. Mice that are not treated with the drug will 
improve their time to escape after doing the test multiple times. 
The SZT injections caused a significant decrease in the mice’s 
improvement in their performance on the test. In comparison, 
the learning and memory behaviors of the thalidomide treated 
mice were significantly better preserved and they were able to 
complete the tests with improved timing, although they were 
not as improved as the mice who did not receive any drugs. 
This positive result appears to be due to the anti-inflammatory 
effect of TNF-alpha inhibition (Elçioğlu, et. al. 2013). 
A second study used a strain of mice with the human 
APPswedish transgenic (APP23) mutation. This mutation is as-
sociated with Alzheimer’s Disease. These mutated mice show 
deficits in spatial memory which become severe with age.  (The 
Jackson Laboratory Website. 2018) This report showed that 
thalidomide treatment improved memory and learning ability 
in the mutated mice. The level of TNF-alpha in the thalidomide 
treated mice was decreased. This in turn reduced the amount of 
amyloid (A beta 1-42,) a harmful protein, which accumulated in 
their brain tissue. The control group mice treated with the inac-
tive vehicle had 750 units of harmful amyloid, while the thalido-
mide group had only approximately 100 units (He, et. al. 2013).
In mice brain tissue, the control group (treated with the vehi-
cle) developed a large number of harmful senile plaques but the 
thalidomide treated group showed very few.
Adverse Effects of Thalidomide
This section summarizes the adverse effects of thalidomide, some 
of which have also been mentioned previously. Thalidomide was 
withdrawn from widespread use shortly after the devastating 
effects on developing embryos was discovered. The drug came 
back into limited use for malignant and inflammatory diseases 
in non-pregnant women.  It can still have serious harmful effects: 
peripheral neuropathy (pain and tingling in the hands and feet), 
venous thrombosis (blood clots in the veins), skin rashes, consti-
pation, somnolence (excessive daytime sleepiness), weakness, and 
bradycardia (BC Cancer Drug Index. updated 2018).
Peripheral neuropathy is a common side effect that is associ-
ated with prolonged use of the drug, but there is no clear mech-
anism of action that explains its correlation with a cumulative 
dose. The risk for nerve damage is highest after 6 months or 
more of therapy. The symptoms are usually reversible when the 
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patient stops thalidomide treatment, although some patients do 
suffer long term nerve damage (Rajkumar, et. al. 2002).
Constipation caused by thalidomide can vary from mild to se-
vere. As many as 90% of patients can develop mild constipation. 
This effect is thought to be secondary to thalidomide’s action 
on the autonomic nerve endings in the gut. Severe constipation 
usually occurs in patients who are taking high doses of thalido-
mide. It is especially prevalent among patients who are already 
prone to developing constipation, such as those who lead an 
inactive lifestyle. Change of diet and exercise can help alleviate 
this side effect (Hall, 2003).
Deep vein thrombosis and pulmonary embolisms only occur 
in one to three percent of the patients receiving thalidomide 
as treatment for myeloma. There is not enough research done 
yet to determine whether the risk of DVT in these patients is 
higher than usual for patients receiving other types of treatment 
for this severe malignancy, due to the nature of the disease or 
the side effect of immobility that it can cause. Patients confined 
to bed rest tend to have higher rates of DVT. The risk is also 
elevated when patients receive thalidomide treatment in combi-
nation with dexamethasone or other chemotherapy drugs, have 
an inherited thrombotic predisposition, or are over the age of 
sixty-five (Hall, 2003).
A recent case report documents a thirty-eight-year-old fe-
male from Puerto Rico with a history of prenatal thalidomide 
exposure. She suffered from phocomelia, the dramatic birth 
defect in which the hands or feet are attached close to the 
trunk. An MRI scan revealed that the uterus and vagina were 
also absent. These internal anomalies have been less appreciated 
by physicians because they are not noticeable without special 
imaging, however they can cause serious symptoms such as pain 
and malignancy (Dotters-Katz, et. al. 2013).
The analog drug, lenalidomide, has not been found to be 
teratogenic in rabbits, a sensitive species used to detect birth 
defects. However, it may still have adverse effects such as mor-
billiform rashes (Huang, et. al. 2008). In a study done at Mount 
Sinai Medical Center in New York City, doctors found that 7.2% 
of the 806 patients receiving IMiD treatment developed rashes. 
In almost all cases, the rashes could be managed without hav-
ing to discontinue treatment. Thus, it appears that lenalidomide 
may lack some of the adverse effects of thalidomide, while still 
having superior immunomodulatory and antiangiogenic efficacy 
than its parent drug (Barley, et. al. 2016).
An additional analog, Pomalidomide, is now an approved 
drug for MM. A research study conducted in Aberdeen, United 
Kingdom analyzed its effect on zebrafish and chicken embryos. 
The tests showed no detectable teratogenic, antiangiogenic or 
neurotoxic effects. Despite having less side effects, it has more 
anti-inflammatory properties than either thalidomide or lenalid-
omide (Mahony, et. al. 2013).
Conclusion
The psalmist wrote, “The stone that the builders rejected became 
a cornerstone.” (Psalm 118:22) This report illustrates this concept 
as it pertains to the drug, thalidomide. This drug was universally 
banned due to its harmful side-effects. Years later it was found to 
have unique healing properties in several serious diseases.
It appears that the continued use and development of thalid-
omide treatments is justified. Although it can have many serious 
side effects, specifically crippling teratogenesis, it is often the 
last resort as treatment for patients suffering serious diseases. 
Care should be taken to prevent pregnant women from using 
this drug to avoid causing birth defects. Given the significance of 
these effects, the future of thalidomide is not in the drug itself 
but in the derivatives that are now being tested. Lenalidomide 
and pomalidomide are more effective and have less toxic effects. 
As scientists continue to discover their specific mechanisms of 
action they will be able to alter the drug to have even less ad-
verse effects and help more patients worldwide. The prognosis 
for PFS and OS for patients with MM and other forms of can-
cer will decrease even more and give the people suffering with 
these diseases hope for their future. With this new and exciting 
research thalidomide and its analogs have justly become import-
ant medical treatments. 
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